Octanate

Octanate is a plasma-derived, highly purified concentrate of human blood coagulation factor VIII, used for the treatment and prevention of bleeding in patients with haemophilia A (congenital factor VIII deficiency). It acts as a replacement therapy to restore deficient or absent endogenous factor VIII, an essential protein involved in the blood clotting cascade. Mechanistically, it serves as a cofactor for activated factor IX to convert factor X to its active form (Xa), which ultimately leads to thrombin generation and fibrin clot formation. Octanate is also approved for immune tolerance induction (ITI) therapy in patients who develop inhibitors against FVIII. The product contains von Willebrand Factor (VWF) and undergoes double virus-inactivation steps during manufacturing for enhanced safety. Developed by Octapharma, it has been licensed since 1998 and is approved in over 80 countries.

Brand names

OctanateOctanate LV

Other names

human coagulation factor VIIIantihemophilic factor VIII (human)